CN110637034B - Cxcr2抗体及其用途 - Google Patents

Cxcr2抗体及其用途 Download PDF

Info

Publication number
CN110637034B
CN110637034B CN201880027752.3A CN201880027752A CN110637034B CN 110637034 B CN110637034 B CN 110637034B CN 201880027752 A CN201880027752 A CN 201880027752A CN 110637034 B CN110637034 B CN 110637034B
Authority
CN
China
Prior art keywords
seq
antibody
variable region
chain variable
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027752.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110637034A (zh
Inventor
C·R·麦凯
R·M·罗伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900656A external-priority patent/AU2017900656A0/en
Application filed by Monash University filed Critical Monash University
Publication of CN110637034A publication Critical patent/CN110637034A/zh
Application granted granted Critical
Publication of CN110637034B publication Critical patent/CN110637034B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880027752.3A 2017-02-27 2018-02-27 Cxcr2抗体及其用途 Active CN110637034B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900656 2017-02-27
AU2017900656A AU2017900656A0 (en) 2017-02-27 CXCR2 antibodies
PCT/IB2018/000253 WO2018154391A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN110637034A CN110637034A (zh) 2019-12-31
CN110637034B true CN110637034B (zh) 2023-10-10

Family

ID=63253562

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027752.3A Active CN110637034B (zh) 2017-02-27 2018-02-27 Cxcr2抗体及其用途

Country Status (8)

Country Link
US (1) US11053319B2 (enExample)
EP (1) EP3585816A4 (enExample)
JP (2) JP7562258B2 (enExample)
KR (1) KR102673489B1 (enExample)
CN (1) CN110637034B (enExample)
AU (1) AU2018224391B2 (enExample)
CA (1) CA3054616A1 (enExample)
WO (1) WO2018154391A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES
BR112021001683A2 (pt) * 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
KR20220092859A (ko) 2019-09-04 2022-07-04 상하이테크 유니버시티 항-cxcr2 항체 및 이의 용도
EP4330286A4 (en) * 2021-04-26 2025-04-16 Kaohsiung Medical University ANTI-CXCR2 ANTIBODIES AND THEIR USES
KR102952495B1 (ko) * 2023-06-28 2026-04-16 (재) 스크립스코리아항체연구원 항-cxcr2 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328512A (zh) * 2010-11-08 2013-09-25 诺瓦提斯公司 Cxcr2结合多肽
WO2014170317A1 (en) * 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328512A (zh) * 2010-11-08 2013-09-25 诺瓦提斯公司 Cxcr2结合多肽
WO2014170317A1 (en) * 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
a combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2(CXCR2);Ronald S Boshuizen等;《mAbs》;20141215;第6卷;第1415-1424页 *
discrete steps in binding and signaling of interleukin-8 with its receptor;Lijun Wu等;《the Journal of Biological Chemistry》;19961206;第271卷(第49期);第31202-31209页 *

Also Published As

Publication number Publication date
WO2018154391A1 (en) 2018-08-30
JP2020508074A (ja) 2020-03-19
US11053319B2 (en) 2021-07-06
CN110637034A (zh) 2019-12-31
EP3585816A1 (en) 2020-01-01
AU2018224391B2 (en) 2025-06-12
JP2023052023A (ja) 2023-04-11
CA3054616A1 (en) 2018-08-30
AU2018224391A1 (en) 2019-09-19
JP7562258B2 (ja) 2024-10-07
KR20190123753A (ko) 2019-11-01
KR102673489B1 (ko) 2024-06-07
EP3585816A4 (en) 2020-12-30
US20190016809A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20220220218A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
US11479610B2 (en) Anti-IL1RAP antibody
WO2021185273A1 (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
JP2022545300A (ja) 新規の抗ｓｉｒｐａ抗体
JP2023052023A (ja) Ｃｘｃｒ２抗体及びその使用
US20190352390A1 (en) Antibodies to il-37
JP6689847B2 (ja) がんの治療における使用のための抗−ｃｋ８抗体
KR20230132544A (ko) 신규한 항-그렘린1 항체
TW202313699A (zh) 新型抗ｓｉｒｐａ抗體
TW202227498A (zh) 新型抗ｃｌａｕｄｉｎ１８抗體
KR102356187B1 (ko) 항-gm-csf 항체 및 이것의 사용
CA3169980A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
KR20230142768A (ko) Ccdc112를 기반으로 하는 종양세포 성장을 억제하는 방법 및 적용
US20240317880A1 (en) Epithelial Cadherin-Specific Antibodies
JP2024105315A (ja) 炎症を治療する方法
HK40106257A (zh) 新型抗sirpa抗体
AU2022240549A1 (en) Semenogelin neutralizing antibody and epitope and application thereof
HK40067153A (en) Anti-cd47 antibodies and uses thereof
HK40085179A (en) Antibody molecules to c5ar1 and uses thereof
HK40067153B (en) Anti-cd47 antibodies and uses thereof
HK40009395A (en) Antibodies to il-37
HK1253584B (en) Antibody therapeutics that bind cd38

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant